Disclosed are methods useful for the topical therapeutic treatment of cervical intraepithelial neoplasia (CIN) and/or cervical cancer using compositions containing nanoparticles of paclitaxel or other taxanes.

A method of treating cervical intraepithelial neoplasia (CIN) or cervical cancer in a subject is disclosed. The method can include topically administering to an affected area of the subject a composition comprising a plurality of taxane nanoparticles, thereby treating the CIN or the cervical cancer. The taxane nanoparticles can be uncoated (neat) individual particles that are not encapsulated in, bound to, or conjugated to any substance.

The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or polyurethane and a method of providing birth control using the vaginal system wherein a secondary contraception is employed when the vaginal system is removed or expelled from the vagina for specified amounts of time during any of the product-use cycles.

Ammonia oxidizing microorganism preparations for delivery to the urogenital system, kits including ammonia oxidizing preparations for delivery to the urogenital system, and devices for administering ammonia oxidizing preparations to the urogenital system are provided.

Methods of introducing ammonia oxidizing microorganisms to the urogenital system are provided. Methods of treating disorders, including urogenital disorders and inflammatory disorders, with ammonia oxidizing microorganism preparations are provided.

This disclosure provides pharmaceutical compositions for delivering estradiol to a subject in need thereof, as well as methods of administering the compositions, and methods of using them.

According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.

The present invention provides a method of preventive and/or curative treatment of viral infections caused by viruses of the family Papillomaviridae in a subject by administering a therapeutically effective amount of a composition to the subject, wherein the composition comprises of at least one metal ascorbo-camphorate compound, a physiologically acceptable aqueous solvent, and at least one physiologically acceptable excipient, and wherein the metal ascorbo-camphorate compound is Zinc tetra-ascorbo-camphorate referred to as C14. Further, the present invention provides a pharmaceutical composition directed against viral infections caused by viruses of the family Papillomaviridae, the pharmaceutical composition comprising: (a) one metal ascorbo-camphorate compound; (b) a physiologically acceptable aqueous solvent; and (c) at least one physiologically acceptable excipient, wherein the metal ascorbo-camphorate compound is Zinc tetra-ascorbo-camphorate referred to as C14 as well as its use in the preventive and/or curative treatment of viral infections caused by viruses of the family Papillomaviridae. Also provided are a method for the preparation of the said pharmaceutical composition.

A method for treating the gastrointestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

A contraceptive device for intervaginal use includes a relatively thin, saucer-shaped impermeable body having two opposite side faces wherein one of the two side faces is concave in form and the other of the side faces is convex in form. In addition, the impermeable portion includes an amount of copper-including material which is disposed across the side faces of the impermeable portion so that the copper-including material is exposed at locations across the side faces.